Expect heavy selling pressure as market prices in extreme dilution and the resale registration clears. The Series A-2 options are exercisable immediately upon registration, creating near-term overhang. Risk of continued cash burn and further raises is high given the company's prior disclosure of needing additional funding.
Price Chart
Executive Summary
Arcadia Biosciences announces a private placement of ~3.88M common shares (or pre-funded warrants) plus two series of preferred investment options for ~$4M gross proceeds, priced at $1.03 per share at-the-market under Nasdaq rules.
Key Financial Metrics
Key Facts
- 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options for up to 3,883,496 shares each, all priced at $1.03/share.
- Gross proceeds of ~$4M before fees; net proceeds for working capital and general corporate purposes.
- Series A-1 options exercisable at $0.91/share after stockholder approval, expiring 5 years from approval; Series A-2 options exercisable at $0.91/share immediately, expiring 24 months from resale registration effective date.
- Offering is a private placement under Section 4(a)(2)/Reg D, with a resale registration statement to be filed.
- Expected closing on or about June 12, 2026; H.C. Wainwright & Co. as exclusive placement agent.
- Market cap of only $2M; offering size ($4M) equals 200% of market cap, implying massive potential dilution.
Financial Impact
Gross proceeds ~$4M on a $2M market cap; share count potentially tripling. Dilution severe even without including the two tranches of investment options.
Risk Factors
- Dilution could exceed 200% of current shares outstanding, crushing per-share metrics.
- Series A-1 and A-2 investment options add additional overhang; A-2 exercisable immediately upon resale registration.
- Company flagged it may need additional future funding in its 10-K — this offering may not be the last.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310862 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | SC 13G | $0.2800 | awaiting T+60 | — | $0.1518 (−45.79%) |
Sep 15, 2026 5w ago | 8-K | $0.4310 | awaiting T+60 | — | $0.1518 (−64.78%) |
Jul 9, 2026 15w ago | EFFECT | $0.6755 $0.2882 | ▲ +57.34% | ▲ +58.97% | $0.1518 (+77.53%) |
Jul 2, 2026 16w ago | 8-K | $0.7330 $0.3080 | ▼ −57.98% | ▼ −61.55% | $0.1518 (−79.29%) |
Jun 26, 2026 17w ago | S-3 | $0.7190 $0.4480 | ▲ +37.69% | ▲ +42.08% | $0.1518 (+78.89%) |
Jun 15, 2026 19w ago | 8-K | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1518 (+83.47%) |
Jun 12, 2026 19w ago | Press Release | $0.9183 $0.4797 | ▲ +47.76% | ▲ +48.77% | $0.1518 (+83.47%) |
Jun 12, 2026 19w ago | Press Release | $0.9180 $0.4530 | ▲ +50.65% | ▲ +51.31% | $0.1518 (+83.46%) |
May 14, 2026 23w ago | 8-K | $0.9560 $0.6699 | ▲ +29.93% | ▲ +34.44% | $0.1518 (+84.12%) |
Apr 30, 2026 25w ago | 10-K/A | $1.12 $0.6300 | ▼ −43.75% | ▼ −46.82% | $0.1518 (−86.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers